Trevena CEO to Present at the 17th Annual BIO CEO & Investor Conference
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present a company overview at the 17th Annual BIO CEO & Investor Conference on Tuesday February 10, 2015 at 8:00 a.m. EST in New York City.
To access the live audio webcast of the presentation, please visit the “Investors” section of the Company's website at www.trevenainc.com. Following the conclusion of the presentation, the webcast will be archived for 30 days.
About Trevena
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified - TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (Preclinical).
Investor Contacts:
Trevena, Inc.
Jonathan Violin
Director
of investor relations
(610) 354-8840 x231
jviolin@trevenainc.com
or
Argot
Partners
Andrea Rabney
President and chief executive officer
(212)
600-1902
andrea@argotpartners.com
or
Media
Contact:
Argot Partners
Eliza Schleifstein
(917)
763-8106
eliza@argotpartners.com
Source: Trevena, Inc.
Released February 3, 2015